Should Amgen's T-Vec Results Be Questioned?
April 28, 2015 at 16:35 PM EDT
In a report published Tuesday, BofA Merrill Lynch analysts maintained a Neutral rating on Amgen, Inc. (NASDAQ: AMGN), with a price ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.